Cargando…
Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma
Interleukin-12 (IL-12) is a promising candidate for cancer immunotherapy because of its ability to activate a number of host immune subsets that recognize and destroy cancer cells. We found that human hepatocellular carcinoma (HCC) patients with higher than median levels of IL-12 have significantly...
Autores principales: | Lai, Ian, Swaminathan, Srividya, Baylot, Virginie, Mosley, Adriane, Dhanasekaran, Renumathy, Gabay, Meital, Felsher, Dean W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247677/ https://www.ncbi.nlm.nih.gov/pubmed/30458889 http://dx.doi.org/10.1186/s40425-018-0431-x |
Ejemplares similares
-
Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC)
por: Dhanasekaran, Renumathy, et al.
Publicado: (2017) -
MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC
por: Dhanasekaran, Renumathy, et al.
Publicado: (2020) -
MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies
por: Swaminathan, Srividya, et al.
Publicado: (2020) -
MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity
por: Dhanasekaran, Renumathy, et al.
Publicado: (2020) -
MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint
por: Smith, Benjamin A. H., et al.
Publicado: (2023)